For the

individual patient estimates see electronic supplementary material, tables S6 and $7. 3

é

parameter HPV16 E6 HPV16 E7 =

estimate rs.e. (in %) estimate rs.e. (in %) é

a

power-law decay rate Ad) 0.242 9.04 0.268 11.0 s

scaling constant 6 (d) 1.083 777 1379 15.6 a

AIC — 144.58 322.42 a

mean S.e. mean S.e. 2

time to 50% reduction of ty (d) 56.94 26.12 56.29 18.97 z

individual antibody levels A(t) s

~

x

>

antibodies are less affected. Patients who suffered from antibodies can only be detected at the time of cancer diagno- S

residual disease or relapse during or after the follow-up sis [6,7], while in OPC patients, E6 and E7 antibodies canbe

showed lower HPV16 E6 antibody decay proportions than detected 10 and more years prior to diagnosis [12,13]. This %

those who did not recur, but this was not statistically signifi- difference has been attributed to the fact that the main sites S
cant, and not consistent across the tested antigens. This may of HPV-driven OPC, ie. the palatine and lingual tonsils,
be explained by less interaction of the recurring lesion with belong to the Waldeyer’s ring of head and neck lymphoid
lymphatic tissue due to radical lymphadenectomy in the tissue epithelium which may trigger early seroconversion
course of surgery. A higher number of seropositive cases in [46], while immunosurveillance of the cervix uteri is much
nodal stage-positive patients compared to nodal stage-nega- less pronounced.